CABOTEGRAVIR; RILPIVIRINE | N212888 | VIIV HEALTHCARE CO
| Patent # | Expiration | PED | Drug Substance | Drug Product | Use Code | Delist |
|---|---|---|---|---|---|---|
| RE50189 | Nov 27, 2031 | — | — | — | — | |
| 8410103 | Feb 4, 2031 | — | Yes | Yes | — | |
| 10927129 | Apr 28, 2026 | — | Yes | Yes | — | — |
| 11224597 | Sep 15, 2031 | — | — | Yes | — | |
| 11389447 | Jun 30, 2027 | — | — | — | — | |
| 11389448 | Apr 13, 2032 | — | — | Yes | — | — |
| 12138264 | Sep 15, 2031 | — | — | Yes | — | |
| 12178815 | Jul 18, 2038 | — | — | — | — | |
| 12636285 | Oct 1, 2040 | — | — | — | — | |
| 12636286 | Oct 1, 2040 | — | — | — | — |
| Code | Date | Status |
|---|---|---|
| NCE | Jan 21, 2026 | Expired |
ViiV Healthcare added U.S. Patent No. 12,636,285 to the Orange Book listing for Cabenuva (cabotegravir; rilpivirine) NDA 212888.
New: New record
VIIV Healthcare added U.S. Patent 12,636,286 to the Orange Book for CABENUVA KIT (cabotegravir; rilpivirine) under NDA 212888.
New: New record
ViiV Healthcare added patent 12636285 (covering cabotegravir and rilpivirine in CABENUVA KIT) to the Orange Book for NDA 212888.
New: New record
ViiV Healthcare removed restricted distribution (REMS) requirement for Cabenuva (cabotegravir; rilpivirine), changing the product's risk evaluation and mitigation strategy status from Yes to No.
Old: Yes
New: No
VIIV Healthcare added U.S. Patent 12,636,286 to the Orange Book for CABENUVA KIT (cabotegravir; rilpivirine), NDA 212888.
New: New record